Clinical trials: Refractory Ulcerative Colitis
Ulcerative Colitis
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
- Trial name
- NCT03760003
- Testing
- ABX464 100 mg, ABX464 50 mg, ABX464 25 mg
- Where
- 130 sites in United States, Austria and 15 more
- Volunteers
- 355 people
- Sponsor
- Abivax S.A.
Colitis, Ulcerative, Bowel Diseases, Inflammatory
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
This multicenter study is being conducted to determine whether infliximab exposure after an initial infusion is predictive of early clinical response in hospitalized pediatric patients with severe steroid-refractory UC or IBD-U.
- Trial name
- ARCH (NCT02799615)
- Testing
- Infliximab
- Where
- 7 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Ulcerative Colitis
Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.
- Trial name
- NCT00307827
- Testing
- Visilizumab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 38 people
- Sponsor
- Abbott
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Acute Severe Ulcerative Colitis
Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result…
- Trial name
- NCT07297069
- Testing
- Infliximab, Tofacitinib
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asian Institute of Gastroenterology, India
Ulcerative Colitis
Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC
To evaluate the efficacy and safety of Neihulizumab (ALTB-168) administered intravenously in patients with moderate to severe active ulcerative colitis who are refractory or intolerant to anti-Tumor Necrosis Factor α and/or…
- Trial name
- TNF (NCT03298022)
- Testing
- ALTB-168
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- AltruBio Inc.
Ulcerative Colitis, Large Intestine
A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis
The participation in this clinical study will last approximately 21 weeks with a 1 week screening period and a 12 weeks treatment duration.
- Conditions
- Ulcerative Colitis, Large Intestine, Diarrhea, Abdominal Pain
- Trial name
- NCT01011322
- Testing
- LT-02
- Where
- 26 sites in Germany, Lithuania and 1 more
- Volunteers
- 156 people
- Sponsor
- Lipid Therapeutics GmbH
Pouchitis
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry.
- Trial name
- NCT00583531
- Testing
- AST-120
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ocera Therapeutics